Optimizing the Cas13 antiviral train: cargo and delivery

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic in 2020 highlighted the need for rapid, widespread responses against infectious disease. One such innovation uses CRISPR‐Cas13 technology to directly target and cleave viral RNA, thereby inhibiting replication. Due to their pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Shruti, Myhrvold, Cameron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331568/
https://www.ncbi.nlm.nih.gov/pubmed/37231981
http://dx.doi.org/10.15252/emmm.202217146
Descripción
Sumario:The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic in 2020 highlighted the need for rapid, widespread responses against infectious disease. One such innovation uses CRISPR‐Cas13 technology to directly target and cleave viral RNA, thereby inhibiting replication. Due to their programmability, Cas13‐based antiviral therapies can be rapidly deployed to target emerging viruses, in comparison with traditional therapeutic development that takes at least 12–18 months, and often many years. Moreover, similar to the programmability of mRNA vaccines, Cas13 antivirals can be developed to target mutations as the virus evolves.

Ejemplares similares